首页> 外国专利> The formulation includes 1h-quinazolina-2, 4-diona derivatives as the target country of AMPA receptor in the form of immediate release tablets and preparation

The formulation includes 1h-quinazolina-2, 4-diona derivatives as the target country of AMPA receptor in the form of immediate release tablets and preparation

机译:该制剂以速释片剂和制剂的形式包含1h-quinazolina-2、4-diona衍生物作为AMPA受体的目标国家/地区

摘要

1. A pharmacological formula in the form of a plate, including: 2% to 10% by weight of each tablet of hydroxypropyl cellulose and 1 h-quinazolina-2.4-diona (I) active compounds, 5% to 27.5% by weight of each tablet, wherein R1 is CF3, chf2, ch2f, CH3CHF, etc.; R2 is Replaced by halogen, nitric acid, cyanogen, etc The most popular formula compounds (I): (I)Page: 1(III)There are others It may also include insoluble water fillers, such as microcrystalline cellulose, with a weight percentage of 25 to 50%; dissolving agents, such as starch glycerin, with a weight percentage of 2.5 to 15%; and other precursors, such as flow assistants and lubricants. This is also a preparation process. These compounds (I) have the activity of antagonizing AMPA receptor
机译:1.板状的药理配方,包括:每片2%至10%重量的羟丙基纤维素和1 h-喹唑啉纳-2.4-二偶氮(I)活性化合物,5%至27.5%重量的每个片剂,其中R1是CF3,chf2,ch2f,CH3CHF等。 R2被卤素,硝酸,氰等取代最受欢迎的分子式(I):(I)页数:1(III)还有其他化合物可能还包括不溶性水填充剂,例如微晶纤维素,按重量百分比计25%至50%;重量百分比为2.5%至15%的溶解剂,例如淀粉甘油;以及其他前体,例如流动助剂和润滑剂。这也是一个准备过程。这些化合物(I)具有拮抗AMPA受体的活性。

著录项

  • 公开/公告号PE20121394A1

    专利类型

  • 公开/公告日2012-10-29

    原文格式PDF

  • 申请/专利权人 NOVARTIS AG;

    申请/专利号PE2012000861

  • 申请日2010-12-21

  • 分类号A61K31/517;A61K9/14;A61K9/16;A61K9/20;

  • 国家 PE

  • 入库时间 2022-08-21 17:23:24

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号